On August 11, 2026, Eric Foster notified Ardelyx, Inc. of his decision to resign as Chief Commercial Officer, effective August 28, 2026. Mr. Foster resigned to pursue a new opportunity with a pre-commercial company, and the resignation is not due to any disagreement with the Company. Ardelyx, Inc. operates in the pharmaceutical industry, developing therapies for gastrointestinal diseases.

Ardelyx, Inc. reported second quarter 2026 financial results with total product revenue of $118.1 million, a 31% year-over-year increase driven by IBSRELA ($86.2 million) and XPHOZAH ($31.9 million). The company revised its full-year 2026 IBSRELA revenue guidance down to $350–$370 million due to increased payor utilization management, while reiterating XPHOZAH guidance of $110–$120 million and lowering operating expense guidance below $500 million. Ardelyx reported a net loss of $16.7 million ($0.07 per share) and holds $281.8 million in cash, cash equivalents, and investments as of June 30, 2026. Additionally, the company drew $50 million from its financing arrangement with SLR Investment Corp. on June 29, 2026, and concluded litigation against CMS regarding XPHOZAH reimbursement classification. Ardelyx is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative medicines for unmet medical needs.

Ardelyx, Inc. drew down $50.0 million of funding from the Term F Loan under its existing loan and security agreement with SLR Investment Corp. and other lenders. The funds are intended for general corporate purposes and to support strategic initiatives. The loan maturity date is July 1, 2030, with an interest rate of 4.55% plus the greater of the 1-month SOFR reference rate or 3.5%. Ardelyx, Inc. is a biotechnology company that develops and commercializes commercial-stage drugs for kidney and gastrointestinal diseases.